請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17241完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳保中 | |
| dc.contributor.author | Chien-Ru Wen | en |
| dc.contributor.author | 溫倩茹 | zh_TW |
| dc.date.accessioned | 2021-06-08T00:02:35Z | - |
| dc.date.copyright | 2013-09-24 | |
| dc.date.issued | 2013 | |
| dc.date.submitted | 2013-08-15 | |
| dc.identifier.citation | 1. Bureau of National Health Insurance. Available from: http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx?now_fod_list_no=12939&class_no=440&level_no=4
2. Francesca Lodato, Giuseppe Mazzella, Davide Festi, Francesco Azzaroli, Antonio Colecchia, Enrico Roda. Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006;12(45):7239-7249 3. Lai MS, Hsieh MS, Chiu YH et al. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43:1295–302 4. Wang CS, Yao WJ, Chang TT et al. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev 2009; 18: 2054–60 5. Wei-Hsu Ko, Sherry Yueh-Hsia Chiu, Kuo-Ching Yang et al. Diabetes, hepatitis virus infection and hepatocellular carcinoma: A case–control study in hepatitis endemic area. Hepatology Research 2012; 42: 774–781 6. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on longterm risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377(9759):31–41. 7. Harris RE, Beebe-Donk J, Alshafie GA. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2008;8(1):237. 8. Sahasrabuddhe VV, Gunja MZ, Graubard BI, et al. Non-steroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 2012;104(23):1808-14 9. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment:p rospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278 10. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: A meta-analysis. JAMA 2006;295:74-80 11. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: A population-based cohort study. Int J Cancer 2005;114:643-647 12. Poynter JN, Gruber SB, Higgins PD, et al: Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-2192 13. Tsan YT, Lee CH, Wang JD et al: Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012;30:623-630 14. Yu-Tse Tsan, Chang-Hsing Lee, Pau-Chung Chen et al: Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection.J Clin Oncol. 2013;31(12):1514-21. 15. P. A. Sakkinen, P. Wahl, M. Cushman et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. American Journal of Epidemiology. 2000;152(10): 897–907 16. C.Wang, X.Wang, G. Gong et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. International Journal of Cancer 2012:130(7):1639–1648 17. C.-J. Weng, Y.-H. Hsieh, C.-M. Tsai et al. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Annals of Surgical Oncology 2010;17(7):1808–1815 18. J. K.Wiencke. Impact of race/ethnicity on molecular pathways in human cancer,” Nature Reviews Cancer 2004;4(1):79–84 19. P. Vigneri, F. Frasca, L. Sciacca et al. Diabetes and cancer. Endocrine-Related Cancer 2009;16(4):1103–1123 20. C. D. Williams, J. Stengel, M. I. Asike et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140(1):124–131 21. G. Vernon, A. Baranova, Z. M. Younossi. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology & Therapeutics 2011;34(3):274–285 22. Masahito Shimizu, Takuji Tanaka, Hisataka Moriwaki. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Seminars in Immunopathology 2013;35(2):191-202 23. Bureau of National Health Insurance. Available from: http://www.nhi.gov.tw/resource/Webdata/23516_1_NO.102全民健保.pdf 24. Centers for Disease Control and Prevention: International Classification of Diseases, Ninth Revision (ICD-9). http://www.cdc.gov/nchs/icd/icd9.htm 25. Cheng CL, Kao YH, Lin SJ, et al: Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmaco epidemiol Drug Saf 2011;20:236-242, 26. Chiu HF, Ho SC, Chen CC, et al: Statin use and the risk of liver cancer: A population-based case control study. Am J Gastroenterol 2011;106:894-898 27. Wu CY, Chen YJ, Lin JT et al. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308(18):1906-14 28. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236 29. WHO Collaborating Center for Drugs Statistics Methodology: ATC/DDD Index 2013. http:// www.whocc.no/atc_ddd_index/ 30. Di Bisceglie AM, Carithers RL Jr, Gores GJ: Hepatocellular carcinoma. Hepatology 28 (4): 1161-5, 1998 31. Parkin DM, Whelan SL, Ferlay J, et al., eds.: Cancer Incidence in Five Continents. Volume VII. Lyon, France: International Agency for Research on Cancer, 1997 32. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G.Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010 May;30(5):750-8. 33. Siddharth Singh, Preet Paul Singh, Abha Goyal Singh et al. Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2013;108(6):881-91. 34. Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27(11):1654-64 35. Stang P, Lydick E, Silberman C, et al: The prevalence of COPD: Using smoking rates to estimate disease frequency in the general population. Chest 2000(suppl 2);117:354S-359S | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17241 | - |
| dc.description.abstract | 研究目的：
根據目前許多動物學及流行病學的結果顯示，糖尿病的族群有比較高的肝癌發生率。陸陸續續亦有流行病學研究顯示statin類用會降低B型肝炎及C型肝炎發生肝癌的風險。流行病學研究亦發現阿斯匹靈可降低大腸癌的風險，但對於其他癌症的風險預防目前並沒一致的結果。本研究希望進一步探討阿斯匹靈與Statin類用藥使用與肝癌發生的關係。 研究方法： 研究設計為利用台灣全民健保資料庫中，篩選出以全國1998至2009年被診斷為糖尿病的新發生個案的世代研究，並追蹤這些個案到2010年12月底止。若在糖尿病發生後365天診斷為肝癌者則為此研究之目標個案。在996,666符合資格的世代個案中，以Cox 比例風險回歸分析法評估阿斯匹靈與Statin類用藥與肝癌風險的關係。 研究結果： 與沒有阿斯匹靈與Statin類用藥的人比較之下，同時使用阿斯匹靈與Statin類用藥的人其罹患肝癌的風險降低，絕對風險比(adjusted hazard ratio)為 0.34 (95% CI, 0.30-0.37)。此外，單用Statin類用藥或阿斯匹靈用藥的人其罹患肝癌的風險亦降低，絕對風險比為0.44 (95% CI, 0.39-0.49)和0.57 (95% CI, 0.53-0.62)。 結論： Statins類藥物的使用會降低糖尿病族群發生肝癌的風險，阿斯匹靈用藥在超過一定累積劑量後亦會降低糖尿病族群發生肝癌的風險，且阿斯匹靈與用藥Statins類藥物在降低糖尿病族群發生肝癌的風險上有加成的效果。此結果值得進一步的研究來確認。 | zh_TW |
| dc.description.provenance | Made available in DSpace on 2021-06-08T00:02:35Z (GMT). No. of bitstreams: 1 ntu-102-R98841004-1.pdf: 740898 bytes, checksum: cd1e0292b6c4a58644f84abc41dd173b (MD5) Previous issue date: 2013 | en |
| dc.description.tableofcontents | Contents
論文口試委員審定書……………………………………………………ii 謝辭……………………………………………………………………iii 摘要……………………………………………………………………iv-v Abstract……………………………………………………………vi-vii Chapter 1 Introduction……………………………………………1-4 Chapter 2 Research Design and Methods ………………………5-11 2.1 Data sources………………………………………………………5 2.2 Study design………………………………………………………6 2.3 Oral medicines Exposure Estimation…………………………7 2.4 Potential confounders……………………………………………8 2.5 Statistical analysis…………………………………………9-11 Chapter 3 Results…………………………………………………12-15 Chapter 4 Discussions……………………………………………16-21 Chapter 5 References……………………………………………22-27 | |
| dc.language.iso | en | |
| dc.title | 糖尿病族群使用阿斯匹靈與Statin類用藥會降低肝癌發生風險 | zh_TW |
| dc.title | Aspirin and Statins reduce the risk of hepatocellular carcinoma in patients with diabetes | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 101-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 陳仲達,何文照,楊南屏,李俊賢 | |
| dc.subject.keyword | 糖尿病,肝癌,Statin用藥,阿斯匹靈, | zh_TW |
| dc.subject.keyword | diabetes,hepatocellular carcinoma,statin,aspirin, | en |
| dc.relation.page | 33 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2013-08-15 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 職業醫學與工業衛生研究所 | zh_TW |
| 顯示於系所單位： | 職業醫學與工業衛生研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-102-1.pdf 未授權公開取用 | 723.53 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。